Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PGXL and Silicon Biosystems Collaborate

Published: Friday, April 26, 2013
Last Updated: Friday, April 26, 2013
Bookmark and Share
Companies to offer clinical research services focused on oncology genomics.

PGXL Technologies and Silicon Biosystems, Inc. announced a collaborative partnership to make the highly regarded Silicon Biosystems DEPArray technology available through PGXL Technologies. The PGXL program will allow clinical researchers and pharma sponsors to obtain the level of data fidelity and resolution needed in cancer biomarker discovery and translational research.

“As the DEPArray technology has gained recognition in the marketplace for its unmatched ability to recover pure cells for molecular characterization, we have received significant interest in having the platform available on a fee-for-service basis,” said Bob Proulx, President and General Manager of Silicon Biosystems’ U.S. operations. “Last year we added a demonstration and training lab, but partnering with PGXL for CRO services will add a whole new dimension to our ability to reach and impact the market.”

The DEPArray technology has broad application in the study of the underlying causes of disease, disease progression and the basis of drug resistance and efficacy. Recent technology progress in the areas of DNA and RNA analysis have shown that the complexity of diseases, like cancer, will require the characterization and comparison of different types of samples at the single cell level. The DEPArray system provides single-cell sorting, and can deliver the cell purity needed for the stringent downstream applications, such as next-gen sequencing and RNA expression profiling.

“We partnered with PGXL because they bring highly complementary capabilities and expertise to the equation,” Proulx continued. “Their experience in molecular methods and operation of a CLIA laboratory make them an ideal service provider for our prospective clients interested in genomic heterogeneity and translational research.”

“PGXL Tech exists to bring to market technologies that advance personalized medicine,” said Dr. Roland Valdes, Jr., President of PGXL Laboratories. “Making the DEPArray available on a fee-for-service basis empowers researchers to work with a precision that will speed discovery.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!